Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aptamer-drug conjugates (ApDCs) are potential targeted pharmaceutics, but their clinical applications are hampered by fast clearance in blood. Herein we report the construction of ApDCs modified with artificial base F and the study of biological activities. Two types of F-base-modified ApDCs were prepared, Sgc8-paclitaxel by conjugation and Sgc8-gemcitabine, by automated solid-phase synthesis. In vitro experiments showed that F-base-modified ApDCs retain the specificity of the aptamer to target cells and the biological stability is improved. In vivo studies demonstrated that the circulatory time is increased by up to 55 h or longer, as the incorporated F base leads to a stable ApDC-albumin complex as the formulation for targeted delivery. Moreover, conjugated drug molecules were released efficiently and the drug (paclitaxel) concentration in the tumor site was improved. The results demonstrate that an F-base-directed ApDC-albumin complex is a potential platform for drug delivery and targeted cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781099 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics14122781 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aptamers as target-specific recognition elements in drug delivery.
Adv Drug Deliv Rev
September 2025
Biochemistry, CUNY Graduate Center, The City University of New York, 365 Fifth Avenue, New York, NY 10016, United States; Molecular, Cellular, and Developmental Biology, CUNY Graduate Center, The City University of New York, 365 Fifth Avenue, New York, NY 10016, United States; Chemistry, CUNY Gradua
Targeted drug delivery significantly enhances therapeutic efficacy across various diseases, particularly in cancer treatments, where conventional approaches such as chemotherapy and radiotherapy often cause severe side effects. In this context, nucleic acid aptamers-short, single-stranded DNA or RNA oligonucleotides capable of binding specific targets with high affinity-have emerged as promising tools for precision drug delivery and therapy. Aptamers can be selected against whole, living cells using SELEX and chemically modified for diverse applications.
View Article and Find Full Text PDFDeveloping Aptamer-Targeted mRNA for Immunotherapy.
Methods Mol Biol
August 2025
Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR.
Selective protein expression plays a crucial role in mRNA therapeutics. In this chapter, we present a novel T-cell-targeting aptamer drug delivery platform that enables efficient mRNA delivery to immune cells for immunotherapy. We outline protocols for aptamer selection, aptamer-mRNA conjugation, characterization, and transfection into T-cells.
View Article and Find Full Text PDF[Advances in cancer stem cell markers and their targeting aptamers].
Sheng Wu Gong Cheng Xue Bao
August 2025
Innovation Center of Molecular Diagnostics, State Key Laboratory of Green Biomanufacturing, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Cancer ranks as the second leading cause of death globally and has surpassed cardiovascular diseases to become the primary cause of mortality in developed countries. Cancer stem cells (CSCs), which play crucial roles in cancer recurrence, metastasis, and drug resistance, have attracted significant attention in targeted therapeutic strategies. Aptamers, with unique three-dimensional structures capable of specifically recognizing the surface markers of CSCs, show promising potential in targeted drug delivery systems.
View Article and Find Full Text PDFNovel Aptamer-Drug Conjugate for Targeted Therapy in Triple-Negative Breast Cancer.
J Med Chem
July 2025
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Triple-negative breast cancer (TNBC) is a highly aggressive malignancy lacking targeted therapeutic modalities. Aptamers are promising targeting agents with high specificity and affinity. In this study, we identified a chemically modified nucleic acid aptamer (AptT1) that specifically recognized and internalized into TNBC cells.
View Article and Find Full Text PDFAnti-nucleolin aptamer-guided anticancer activity of AS1411-Chalcone conjugate in breast cancer.
Biochem Biophys Res Commun
September 2025
Integrated Genetics and Molecular Oncology Group, Department of Genetic Engineering, Faculty of Engineering and Technology, SRM Institute of Science and Technology, SRM Nagar, Potheri, Chengalpattu Dt, Tamil Nadu, 603203, India. Electronic address:
The DNA aptamer AS1411 is a 26-nucleotide, guanine-rich oligonucleotide with high specificity for nucleolin-a multifunctional protein overexpressed on the surface of many cancer cells and involved in key processes such as proliferation and apoptosis. By selectively binding nucleolin, AS1411 serves as an ideal targeting ligand for delivering therapeutic agents. Chalcone, a naturally occurring flavonoid with documented anticancer activity, induces apoptosis and inhibits tumor growth; however, its clinical utility is limited by nonspecific cytotoxicity.
View Article and Find Full Text PDF